TRIUMPH: retatrutide weight loss
The TRIUMPH program reported retatrutide produced up to 24% mean weight loss over 48 weeks — an unprecedented magnitude for a single agent in obesity trials and highly relevant for diabetes prevention/management. That scale of loss changes metabolic risk profiles and could shift how clinicians pair weight‑loss drugs with glucose therapies. (medicaldialogues.in)
The phase‑2 randomized trial enrolled 338 adults without diabetes and used once‑weekly subcutaneous retatrutide at up to four active dose regimens, with a 2:1:1:1:1:2:2 randomization versus placebo. (nejm.org) The trial’s primary endpoint at 24 weeks showed a clear dose–response: least‑squares mean body‑weight changes of −7.2% (1 mg), −12.9% (4 mg), −17.3% (8 mg) and −17.5% (12 mg). (nejm.org) At the longer‑term assessments, the investigational arms produced markedly higher responder rates: among participants on the highest regimen, 100% reached ≥5% weight loss, 93% reached ≥10%, and 83% reached ≥15% at the end of the treatment period. (pharmacytimes.com) Safety data from the phase‑2 report showed dose‑related gastrointestinal events (nausea, diarrhea, vomiting, constipation) as the most frequent adverse events, generally mild‑to‑moderate and mitigated by gradual dose escalation. (nejm.org) In the TRIUMPH‑4 phase‑3 readout (adults with obesity and knee osteoarthritis), the 9 mg and 12 mg regimens met co‑primary endpoints and the company reported a mean weight reduction of up to 28.7% at 68 weeks alongside an average 4.5‑point improvement in WOMAC pain scores. (prnewswire.com) Separately, TRANSCEND‑T2D‑1, Lilly’s first Phase‑3 diabetes trial of retatrutide, met its primary glycemic endpoint with A1C reductions of roughly 1.7%–2.0% at 40 weeks and showed about a 16.8% mean weight reduction on the 12 mg dose (≈36.6 lb). (prnewswire.com) The TRIUMPH program is a multi‑trial Phase‑3 portfolio (including obesity, obstructive sleep apnea, knee osteoarthritis and other comorbidity substudies) that lists individual trial enrollment goals such as 445 participants for TRIUMPH‑4 on company and registry pages. (clinicaltrials.gov)
